title: [Strategy to develop a new drug for treatment-resistant depression--role of electroconvulsive stimuli and BDNF].
abstract: In recent years, depression studies have focused on morphological changes associated with depression. Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor that plays an important role in the morphological changes associated with depression and the mechanisms of antidepressants. On the other hand, hyperfunction of the hypothalamic-pituitary-adrenal axis has been link to pathophysiology of depression. In our previous studies, ACTH-treated rats served as a valuable animal model of tricyclic antidepressant-resistant depressive conditions. However, few neuroanatomic studies have been done. In the present study, we investigated mechanisms underling ACTH-treated rat serving an imipramine treatment-resistant depression model using c-Fos as a marker. The c-Fos immunohistochemical study indicated that the medial prefrontal cortex is an action site of imipramine in ACTH-treated rats. Electroconvulsive therapy is considered an effective treatment for treatment-resistant depression. However, the mechanisms causing treatment-resistant depressive conditions are unknown. We investigated the effect of repeated electrical convulsive shock (ECS)-treatment using the forced swim test, a screening method for antidepressant-like activity, and hippocampal BDNF protein levels in ACTH-treated rats. Findings showed that repeated ECS treatment decreased the immobility time during forced swim test. Furthermore, the ECS treatment also markedly increased the hippocampal BDNF levels in the rat tricyclic antidepressant-resistant depression model. In addition, the repeated ECS treatment showed long-lasting effects on forced swim test and increased of hippocampal BDNF levels in normal rats. These findings suggest that BDNF plays a key role in the antidepressant-like effect of ECS and that increased BDNF may be involved in promoting the long-lasting effect.
authors.affiliation: Department of Clinical Pharmacology and Pharmacy, Brain Science, Ehime University Graduate School of Medicine, Ehime University Hospital, Japan.
authors.forename: Bingjin
authors.initials: B
authors.lastname: Li
authors.forename: Katsuya
authors.initials: K
authors.lastname: Suemaru
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kitamura
authors.forename: Ranji
authors.initials: R
authors.lastname: Cui
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Gomita
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Araki
mesh_terms: D000324:Adrenocorticotropic Hormone; D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism / Q000502:physiology*; D003863:Depression / Q000209:etiology / Q000628:therapy*; D004195:Disease Models, Animal; D015195:Drug Design; D004565:Electroconvulsive Therapy; D006624:Hippocampus / Q000378:metabolism; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology; D010913:Pituitary-Adrenal System / Q000502:physiology; D051381:Rats
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D000324:Adrenocorticotropic Hormone